Shares in Mesoblast tumbled more than 15 per cent on Tuesday after the regenerative medicine company missed the primary goal in a trial of its heart failure treatmentRevascor.
Mesoblast said its 537-patient phase three trial of Revascor mesenchymal precursor cells, used to treat chronic heart failure, had not met its primary end point, but had reduced cardiac deaths.
Loading...
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
